The Head Of The Indonesian National Armed Forces Health Center Ensures Clinical Trials Of Archipelago Vaccines In Accordance With Research Rules

ILLUSTRATION / PIXABAY

JAKARTA - The head of the Indonesian National Armed Forces Health Center, Maj. Gen. Ratmono, will confirm that the second phase of the Nusantara Vaccine clinical trial will be in accordance with the principles of vaccine research and development.

Moreover, the dendritic-based vaccine research process uses TNI facilities, namely the Central Army Hospital (RSPAD) Gatot Soebroto, Jakarta.

"Collaboration is needed and this must be carefully monitored in guarding the research so that in accordance with the rules of this research, it must comply with the applicable regulations," said Ratmono in a press conference in Jakarta, Monday, April 19.

He said, if later this Nusantara Vaccine has met all the provisions, then the next step is to get a recommendation from the Food and Drug Supervisory Agency (BPOM).

This is stated in the rules of cooperation or legal standing between the TNI and the COVID-19 vaccine research team which was initiated by the former Minister of Health (Menkes) Terawan Agus Putranto.

"This is a system of legal standing that must be carried out. Of course in RSPAD there will already be legal standing processes that we have to do and we guard together," said Ratmono.

The TNI continued to support all forms of vaccine research and innovation, especially in the response to the COVID-19 pandemic. However, the research must still be in accordance with the research principles that have been established by the competent agency or institution.

"Of course, this must uphold scientific principles, both the stages of an innovation, including the stages of research," he concluded.